Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma
Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma
复制标题
DOI：
10.3390/ijms20163919
复制
发表时间：
2019-08-02
影响因子：
5.6
通讯作者：
Buechler, Christa
中科院分区：
文献类型：
--
作者：
Feder, Susanne;Kandulski, Arne;Buechler, Christa
趋化剂脂肪因子趋化素与代谢综合征有关，代谢综合征是多种癌症的危险因素。最近的研究表明，趋化素是结直肠癌（CRC）和肝细胞癌（HCC）的重要分子。结直肠癌患者血清趋化素含量高，HCC患者血清趋化素含量低，可作为HCC和结直肠癌肝转移的鉴别诊断指标。为此，采用ELISA法检测36例结直肠癌转移患者、32例HCC患者和49例非肿瘤患者的血清趋化素水平。然而，在三个队列中，趋化素血清蛋白水平相似。高血压患者血清趋化素高于正常肿瘤患者，而非对照组。伴有高胆固醇血症或高尿酸血症的癌症患者血清趋化素也增加。当排除这些合并症的患者时，结直肠癌患者的chemerin高于HCC患者，但与对照组没有差异。在两个队列中，趋化素与肿瘤标志物癌胚抗原、碳水化合物抗原19-9和甲胎蛋白没有相关性，并且在HCC中不随肿瘤-淋巴结-转移阶段而改变。Chemerin与肝脏脂肪、肝脏炎症和纤维化无关。综上所述，全身性趋化素不能区分结直肠癌转移和HCC。肿瘤患者的合并症与全身趋化素升高有关。
The chemoattractant adipokine chemerin is related to the metabolic syndrome, which is a risk factor for different cancers. Recent studies provide evidence that chemerin is an important molecule in colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Serum chemerin is high in CRC patients and low in HCC patients and may serve as a differential diagnostic marker for HCC and liver metastases from CRC. To this end, serum chemerin was measured in 36 patients with CRC metastases, 32 patients with HCC and 49 non-tumor patients by ELISA. Chemerin serum protein levels were, however, similar in the three cohorts. Serum chemerin was higher in hypertensive than normotensive tumor patients but not controls. Cancer patients with hypercholesterolemia or hyperuricemia also had increased serum chemerin. When patients with these comorbidities were excluded from the calculation, chemerin was higher in CRC than HCC patients but did not differ from controls. Chemerin did not correlate with the tumor markers carcinoembryonic antigen, carbohydrate antigen 19-9 and alpha-fetoprotein in both cohorts and was not changed with tumor-node-metastasis stage in HCC. Chemerin was not associated with hepatic fat, liver inflammation and fibrosis. To conclude, systemic chemerin did not discriminate between CRC metastases and HCC. Comorbidities among tumor patients were linked with elevated systemic chemerin.